Dual angiogenic inhibitor for DME posts positive phase 2 results

Genentech presented encouraging data from an ongoing trial investigating the efficacy and safety of RG7716, a novel bispecific antibody that binds to angiopoietin 2 and VEGF.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553